Semaglutide
FDA ApprovedSemaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
Dose
0.25 mg to 2.4 mg
Route
Subcutaneous injection, Oral tablet
Cycle
Ongoing, based on research protocol and individual response
Storage
Lyophilized powder vial: store sealed at 2-8°C protected from light for long-term storage; brief room-temperature exposure during shipping is tolerated. -20°C for extended storage.
What is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that shares 94% sequence homology with native human GLP-1. Its structure includes modifications, such as the substitution of alanine with alpha-aminoisobutyric acid (Aib) at position 2 and the attachment of a C18 fatty diacid to lysine at position 26 (often referred to as position 20 in the modified sequence), which contribute to its extended half-life by protecting it from enzymatic degradation and promoting albumin binding. These modifications enable once-weekly subcutaneous administration or daily oral administration in specific formulations. In research, semaglutide is studied for its ability to enhance glucose-dependent insulin secretion, suppress glucagon secretion, slow gastric emptying, and promote satiety, leading to improved glycemic control and weight reduction.
Key Benefits
- Appetite regulation
- Blood glucose control
- Sustained fat loss
Mechanism of Action
- GLP-1 receptor agonism
- Delayed gastric emptying
Best For
- Weight loss
- Type 2 diabetes support
Body Systems
🐾 Griffin Says...
Molecular Information
Molecular weight
4113.58 g/mol
Length
31 amino acids (modified)
Type
GLP-1 receptor agonist
Amino acid sequence
H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(N-epsilon-(17-carboxy-1-oxoheptadecyl))-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH
Aib at position 2 replaces Ala, and Lys at position 20 is acylated with a C18 fatty diacid, contributing to its prolonged half-life.
Pharmacokinetics
Time to peak
1-3 days (subcutaneous)
Half-life
168 h
Time to clear
Approximately 5-7 weeks after the last dose
Clinical pharmacology data for semaglutide from product monographs and peer-reviewed pharmacokinetic studies.
Research Indications
Type 2 Diabetes Mellitus
Extensively researched for its ability to lower HbA1c, improve fasting and postprandial glucose levels, and reduce the risk of major cardiovascular events in individuals with type 2 diabetes.
Blood Glucose Regulation
Promotes glucose-dependent insulin secretion and suppresses inappropriate glucagon secretion, leading to improved glycemic control.
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Type 2 Diabetes Management (Subcutaneous) | Initiate at 0.25 mg once weekly for 4 weeks. Increase to 0.5 mg once weekly for 4 weeks. Further increase to 1 mg once weekly if additional glycemic control is needed. Max dose: 2 mg once weekly. | Once weekly | Subcutaneous injection |
| Chronic Weight Management (Subcutaneous) | Initiate at 0.25 mg once weekly for 4 weeks. Escalate dose every 4 weeks in 0.25 mg or 0.5 mg increments to reach a maintenance dose of 2.4 mg once weekly. Max dose: 2.4 mg once weekly. | Once weekly | Subcutaneous injection |
| Type 2 Diabetes Management (Oral) | Initiate at 3 mg once daily for 30 days. Increase to 7 mg once daily. If additional glycemic control is needed after 30 days on 7 mg, increase to 14 mg once daily. Max dose: 14 mg once daily. | Once daily | Oral tablet (taken with a sip of water, at least 30 minutes before the first meal, beverage, or other oral medications of the day) |
| Cardiovascular Outcome Studies | Typically follows diabetes management dosing (up to 2 mg weekly subcutaneous) or weight management dosing (up to 2.4 mg weekly subcutaneous) within large-scale trials. | Once weekly | Subcutaneous injection |
| NAFLD/NASH Research | Often uses doses similar to those for weight management (e.g., escalating to 2.4 mg once weekly). | Once weekly | Subcutaneous injection |
Consistency in administration day is commonly discussed in research protocols to maintain stable blood levels. If the weekly administration day needs to be changed, researchers typically wait at least 2 days after the last dose before administering on the new day.
Peptide Interactions
- Monitor Combination
Insulin Secretagogues (e.g., Sulfonylureas)
Increased risk of hypoglycemia. Researchers commonly consider a dose reduction of the insulin secretagogue when initiating semaglutide.
- Monitor Combination
Insulin
Increased risk of hypoglycemia. Researchers commonly consider a dose reduction of insulin when initiating semaglutide. Frequent blood glucose monitoring is advised.
- Use Caution
Oral Medications
Semaglutide delays gastric emptying, which may affect the absorption of concomitantly administered oral medications. Researchers commonly advise careful monitoring of medications with a narrow therapeutic index (e.g., warfarin) or those that require rapid gastrointestinal absorption.
- Monitor Combination
Thyroid Hormones
No direct pharmacokinetic interaction is typically expected, but individuals with a history of thyroid conditions should be monitored, particularly given the rodent data on C-cell tumors.
- Compatible
Alcohol
No specific contraindication, but excessive alcohol intake can affect blood glucose levels and may exacerbate gastrointestinal side effects in some individuals. Moderate consumption is generally acceptable.
- Compatible
Diuretics
No direct pharmacokinetic interaction is typically expected. However, gastrointestinal adverse reactions (e.g., vomiting, diarrhea) may lead to dehydration and potentially worsen renal function, particularly in individuals taking diuretics. Monitoring for dehydration is commonly advised.
How to Reconstitute
- 1Verify the concentration and volume of the semaglutide solution.
- 2Ensure the solution is clear and colorless. Do not use if it contains particles or is discolored.
- 3Attach a new, sterile needle to the injection pen or syringe, if applicable.
- 4Prime the pen or syringe according to device-specific instructions to remove air.
- 5Dial the prescribed dose as indicated in the research protocol.
- 6Administer the dose subcutaneously as instructed.
What to Expect
- Weeks 1-4: Initial reductions in appetite and modest improvements in blood glucose control may be observed. Nausea or other gastrointestinal side effects are most common during dose escalation.
- Weeks 5-12: More consistent blood glucose reductions and progressive weight loss typically become evident as the dose is titrated upwards. Side effects may stabilize.
- Weeks 13-24: Significant and sustained weight loss often continues. Participants may report enhanced satiety and reduced food cravings.
- Months 6+: Continued maintenance of weight loss and glycemic control. Long-term metabolic benefits are commonly assessed.
- Sustained use: Research protocols often extend for many months or even years to evaluate long-term efficacy and safety.
Side Effects & Safety
| Effect | Frequency | Severity |
|---|---|---|
| Nausea | Common | Mild to moderate |
| Constipation | Common | Mild |
| Pancreatitis | Rare | Severe |
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open CalculatorPeptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.